Adjuvant Atezo, Palbo-PPI Interaction? And More
Oct 28, 2021•20 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
From IMPOWER 010 to NIFTY to CONFIRM to SOLO, there's lots to discuss on this episode.
Adjuvant atezolizumab for select NSCLC patients now FDA approved.
5-year f/u of olaparib maintenance in mBRCA ovarian cancer smells funny: https://doi.org/10.1016/S1470-2045(21)00531-3
CONFIRM: https://doi.org/10.1016/S1470-2045(21)00471-X
NIFTY: https://doi.org/10.1016/S1470-2045(21)00486-1
Palbociclib-PPI Interaction? https://doi.org/10.1016/j.esmoop.2021.100231
For the best experience, listen in Metacast app for iOS or Android